Keryx Biopharma (KERX) Pulls-Back After Ripping Over 160% on Zerenex DAta
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Keryx Biopharmaceuticals (KERX) Selloff 'Unwarranted'
February 4, 2013 2:33 PM ESTLast Friday, Keryx Biopharmaceuticals Inc. (Nasdaq: KERX) stock dropped 22 percent. The massive selloff is being tied to $65 million in equity financing announced last week. According the analysts at Oppenheimer, some investors interpreted this as a signal that the company was planning to market... More
